Colistin: From the shadows to a One Health approach for addressing antimicrobial resistance
Antimicrobial resistance (AMR) poses a serious threat to human, animal, and environmental health worldwide. Colistin has regained importance as a last-resort treatment against multidrug-resistant Gram-negative bacteria. However, colistin resistance has been reported in various Enterobacteriaceae species isolated from several sources. The 2015 discovery of the plasmid-mediated mcr-1 (mobile colistin resistance) gene conferring resistance to colistin was a major concern within the scientific community worldwide. The global spread of this plasmid – as well as the subsequent identification of 10 MCR-family genes and their variants that catalyse the addition of phosphoethanolamine to the phosphate group of lipid A – underscore the urgent need to regulate colistin use, particularly in animal production. This review traces the history of colistin resistance and mcr-like gene identification and examines the impact of policy changes regarding colistin use on the prevalence of mcr-1-positive E. coli and colistin-resistant E. coli from a One Health perspective.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.